Getting your player ready...
TRENTON, N.J. — After a decade as rivals, drugmakers Merck and Roche are teaming up to market their hepatitis C medicines. The move comes as drugs from a new class are about to transform treatment of the tough-to-cure virus.
Merck’s Victrelis, approved Friday, and Incivek from Vertex Pharmaceuticals, expected to be approved soon, are the first new treatments for hepatitis C in about 20 years.
